Prominent Alopetic Lesions of Lichenoid Drug Eruption Treated with Topical Tacrolimus

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Prominent Alopetic Lesions of Lichenoid Drug Eruption Treated with Topical Tacrolimus

Vol. 26 No. 1, 2014 141 Received September 4, 2012, Revised January 11, 2013, Accepted for publication April 2, 2013 Corresponding author: Sung Yul Lee, Department of Dermatology, Soonchunhyang University College of Medicine, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 330-721, Korea. Tel: 82-41-570-2270, Fax: 82-41-578-2270, E-mail: [email protected] This is an Open Access article distribu...

متن کامل

Lichenoid drug eruption associated with Bendamustine

A 65-year-old man had relapsed follicular lymphoma. When he suffered a fifth relapse, he received a regimen containing bendamustine and rituximab (BR). Four weeks later, he presented with systemic erythema, swelling and bullous lesions of lips, the oral cavity, andnasal mucosa and eye pain. He could not open his mouth and had severe pain. Steven–Johnson syndrome/toxic epidermal necrolysis was d...

متن کامل

Lichenoid drug eruption due to eprosartan/hydrochlorothiacide

We report a case of a 66-year-old male who developed an itchy eruption while taking an antihypertonic drug containing eprosartan and hydrochlorothiacide after sun exposure. The lesions resembled a lichenoid appearance that was confirmed by the histological study. There are few reports in the literature of lichenoid reactions to these compounds, so we review the characteristics of themselves as ...

متن کامل

Imatinib mesylate-induced lichenoid drug eruption.

Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of Dermatology

سال: 2014

ISSN: 1013-9087,2005-3894

DOI: 10.5021/ad.2014.26.1.141